Frontier Medicines reports promising lung cancer drug results in early trial
MarioGuti/iStock via Getty Images
Venture-backed Frontier Medicines said its experimental lung cancer drug FMC-376 shrank tumors in 56% of evaluable patients in an early-stage clinical trial, including patients whose cancers had developed resistance to existing treatments. The findings from the Phase 1/2 PROSPER trial were presented at the European Society for Medical Oncology's 2026 congress in Madrid.
The study evaluated FMC-376 in patients with advanced non-small cell lung cancer (NSCLC) carrying a mutation known as KRAS G12C, a genetic alteration that promotes uncontrolled cancer growth. Among 18 patients evaluated for effectiveness at the selected dose, 10 experienced a confirmed reduction in tumor size that met the study's response criteria. The response rate was 67% among nine patients who had never received a KRAS G12C inhibitor and 44% among nine previously treated with such drugs.
Responses lasted a median of 7.5 months, with six of the 10 responding patients still receiving treatment when the data were updated. The disease control rate, which includes patients whose tumors shrank or remained stable, was 89%. Notably, nine of the 10 responders had additional genetic alterations associated with resistance to existing KRAS inhibitors.
Recommended For You
Register for free to keep reading.
Create a free account to get unlimited breaking news and alerts when your stocks move.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.